IL-1 mediates TNF-induced osteoclastogenesis

Shi Wei, Hideki Kitaura, Ping Zhou, F. Patrick Ross, Steven L. Teitelbaum

Research output: Contribution to journalArticle

491 Citations (Scopus)

Abstract

TNF-induced receptor activator NF-κB ligand (RANKL) synthesis by bone marrow stromal cells is a fundamental component of inflammatory osteolysis. We found that this process was abolished by IL-1 receptor antagonist (IL-1Ra) or in stromal cells derived from type IIL-1 receptor-deficient (IL-1RI-deficient) mice. Reflecting sequential signaling of the cytokines TNF and IL-1, TNF induces stromal cell expression of IL-1 and IL-1RI. These data suggest that TNF regulates RANKL expression via IL-1, and, therefore, IL-1 plays a role in TNF-induced periarticular osteolysis. Consistent with this posture, TNF-stimulated osteoclastogenesis in cultures consisting of WT marrow macrophages and stromal cells exposed to IL-1Ra or in cocultures established with IL-1RI-deficient stromal cells was reduced approximately 50%. The same magnitude of osteoclast inhibition occurred in IL-1RI-deficient mice following TNF administration in vivo. Like TNF, IL-1 directly targeted osteoclast precursors and promoted the osteoclast phenotype in a TNF-independent manner in the presence of permissive levels of RANKL. IL-1 is able to induce RANKL expression by stromal cells and directly stimulate osteoclast precursor differentiation under the aegis of p38 MAPK. Thus, IL-1 mediates the osteoclastogenic effect of TNF by enhancing stromal cell expression of RANKL and directly stimulating differentiation of osteoclast precursors.

Original languageEnglish (US)
Pages (from-to)282-290
Number of pages9
JournalJournal of Clinical Investigation
Volume115
Issue number2
DOIs
StatePublished - Feb 1 2005
Externally publishedYes

Fingerprint

Interleukin-1
Osteogenesis
Stromal Cells
Osteoclasts
Interleukin-1 Receptors
Osteolysis
Tumor Necrosis Factor Receptors
p38 Mitogen-Activated Protein Kinases
Coculture Techniques
Posture
Mesenchymal Stromal Cells
Bone Marrow
Macrophages
Cytokines
Ligands
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wei, S., Kitaura, H., Zhou, P., Patrick Ross, F., & Teitelbaum, S. L. (2005). IL-1 mediates TNF-induced osteoclastogenesis. Journal of Clinical Investigation, 115(2), 282-290. https://doi.org/10.1172/JCI200523394

IL-1 mediates TNF-induced osteoclastogenesis. / Wei, Shi; Kitaura, Hideki; Zhou, Ping; Patrick Ross, F.; Teitelbaum, Steven L.

In: Journal of Clinical Investigation, Vol. 115, No. 2, 01.02.2005, p. 282-290.

Research output: Contribution to journalArticle

Wei, S, Kitaura, H, Zhou, P, Patrick Ross, F & Teitelbaum, SL 2005, 'IL-1 mediates TNF-induced osteoclastogenesis', Journal of Clinical Investigation, vol. 115, no. 2, pp. 282-290. https://doi.org/10.1172/JCI200523394
Wei, Shi ; Kitaura, Hideki ; Zhou, Ping ; Patrick Ross, F. ; Teitelbaum, Steven L. / IL-1 mediates TNF-induced osteoclastogenesis. In: Journal of Clinical Investigation. 2005 ; Vol. 115, No. 2. pp. 282-290.
@article{fcb6da392d974f9fbc0aa2ae3ab4214e,
title = "IL-1 mediates TNF-induced osteoclastogenesis",
abstract = "TNF-induced receptor activator NF-κB ligand (RANKL) synthesis by bone marrow stromal cells is a fundamental component of inflammatory osteolysis. We found that this process was abolished by IL-1 receptor antagonist (IL-1Ra) or in stromal cells derived from type IIL-1 receptor-deficient (IL-1RI-deficient) mice. Reflecting sequential signaling of the cytokines TNF and IL-1, TNF induces stromal cell expression of IL-1 and IL-1RI. These data suggest that TNF regulates RANKL expression via IL-1, and, therefore, IL-1 plays a role in TNF-induced periarticular osteolysis. Consistent with this posture, TNF-stimulated osteoclastogenesis in cultures consisting of WT marrow macrophages and stromal cells exposed to IL-1Ra or in cocultures established with IL-1RI-deficient stromal cells was reduced approximately 50{\%}. The same magnitude of osteoclast inhibition occurred in IL-1RI-deficient mice following TNF administration in vivo. Like TNF, IL-1 directly targeted osteoclast precursors and promoted the osteoclast phenotype in a TNF-independent manner in the presence of permissive levels of RANKL. IL-1 is able to induce RANKL expression by stromal cells and directly stimulate osteoclast precursor differentiation under the aegis of p38 MAPK. Thus, IL-1 mediates the osteoclastogenic effect of TNF by enhancing stromal cell expression of RANKL and directly stimulating differentiation of osteoclast precursors.",
author = "Shi Wei and Hideki Kitaura and Ping Zhou and {Patrick Ross}, F. and Teitelbaum, {Steven L.}",
year = "2005",
month = "2",
day = "1",
doi = "10.1172/JCI200523394",
language = "English (US)",
volume = "115",
pages = "282--290",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - IL-1 mediates TNF-induced osteoclastogenesis

AU - Wei, Shi

AU - Kitaura, Hideki

AU - Zhou, Ping

AU - Patrick Ross, F.

AU - Teitelbaum, Steven L.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - TNF-induced receptor activator NF-κB ligand (RANKL) synthesis by bone marrow stromal cells is a fundamental component of inflammatory osteolysis. We found that this process was abolished by IL-1 receptor antagonist (IL-1Ra) or in stromal cells derived from type IIL-1 receptor-deficient (IL-1RI-deficient) mice. Reflecting sequential signaling of the cytokines TNF and IL-1, TNF induces stromal cell expression of IL-1 and IL-1RI. These data suggest that TNF regulates RANKL expression via IL-1, and, therefore, IL-1 plays a role in TNF-induced periarticular osteolysis. Consistent with this posture, TNF-stimulated osteoclastogenesis in cultures consisting of WT marrow macrophages and stromal cells exposed to IL-1Ra or in cocultures established with IL-1RI-deficient stromal cells was reduced approximately 50%. The same magnitude of osteoclast inhibition occurred in IL-1RI-deficient mice following TNF administration in vivo. Like TNF, IL-1 directly targeted osteoclast precursors and promoted the osteoclast phenotype in a TNF-independent manner in the presence of permissive levels of RANKL. IL-1 is able to induce RANKL expression by stromal cells and directly stimulate osteoclast precursor differentiation under the aegis of p38 MAPK. Thus, IL-1 mediates the osteoclastogenic effect of TNF by enhancing stromal cell expression of RANKL and directly stimulating differentiation of osteoclast precursors.

AB - TNF-induced receptor activator NF-κB ligand (RANKL) synthesis by bone marrow stromal cells is a fundamental component of inflammatory osteolysis. We found that this process was abolished by IL-1 receptor antagonist (IL-1Ra) or in stromal cells derived from type IIL-1 receptor-deficient (IL-1RI-deficient) mice. Reflecting sequential signaling of the cytokines TNF and IL-1, TNF induces stromal cell expression of IL-1 and IL-1RI. These data suggest that TNF regulates RANKL expression via IL-1, and, therefore, IL-1 plays a role in TNF-induced periarticular osteolysis. Consistent with this posture, TNF-stimulated osteoclastogenesis in cultures consisting of WT marrow macrophages and stromal cells exposed to IL-1Ra or in cocultures established with IL-1RI-deficient stromal cells was reduced approximately 50%. The same magnitude of osteoclast inhibition occurred in IL-1RI-deficient mice following TNF administration in vivo. Like TNF, IL-1 directly targeted osteoclast precursors and promoted the osteoclast phenotype in a TNF-independent manner in the presence of permissive levels of RANKL. IL-1 is able to induce RANKL expression by stromal cells and directly stimulate osteoclast precursor differentiation under the aegis of p38 MAPK. Thus, IL-1 mediates the osteoclastogenic effect of TNF by enhancing stromal cell expression of RANKL and directly stimulating differentiation of osteoclast precursors.

UR - http://www.scopus.com/inward/record.url?scp=14944371405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944371405&partnerID=8YFLogxK

U2 - 10.1172/JCI200523394

DO - 10.1172/JCI200523394

M3 - Article

C2 - 15668736

AN - SCOPUS:14944371405

VL - 115

SP - 282

EP - 290

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -